Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22712661 | 0.93 | MGLL (0.37) | PSMB8PSMB5MGLLMAPTALOX12 | |
| SCHEMBL310052 | 0.93 | MGLL (0.37) | PSMB8PSMB5MGLLMAPTALOX12 | |
| 2-Methoxyethanol SCHEMBL29386411 | 0.92 | HPGD (0.35) | ADRA2AADRA1APSMB8PSMB5MGLL | |
| SCHEMBL28342168 | 0.92 | DGKA (0.40) | PSMB8PSMB5MGLLALOX12 | |
| SCHEMBL28192296 | 0.92 | DGKA (0.40) | PSMB8PSMB5MGLLALOX12 | |
| SCHEMBL141048 | 0.91 | ADRA2A (0.36) | ADRA2AADRA1APSMB8PSMB5MGLL | |
| SCHEMBL28680314 | 0.91 | EPHX2 (0.34) | ADRA2AADRA1APSMB8PSMB5TDP1 | |
| SCHEMBL15760611 | 0.90 | PRKCA (0.33) | ADRA2AADRA1APSMB8PSMB5MAPT | |
| SCHEMBL4908861 | 0.89 | — | — | |
| Ethylene Glycol SCHEMBL999673 | 0.87 | PSMB8 (0.36) | PSMB8PSMB5MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114099784-A | Injection type skin filling composition and preparation method and application thereof | 四川兴科蓉药业有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| CN-108601819-A | Amelioration of systemic sclerosis with death receptor agonists | 约翰霍普金斯大学 | 2018-09-28 | — | — | CN | claimed |
| CN-101056595-B | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2012-02-08 | — | — | CN | claimed |
| EP-1578450-A4 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2009-06-17 | — | — | EP | claimed |
| EP-1824414-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MicroVention, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| US-7201918-B2 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2007-04-10 | — | — | US | claimed |
| EP-1585758-A4 | PEPTIDES HAVING PROTECTED AMINES OF UNTARGETED SITES, METHODS FOR PRODUCTION THEREOF AND OF SPECIFICALLY CONJUGATED PEG PEPTIDES USING THE SAME | PEGSPHERE CO LTD (KR) | 2006-06-07 | — | — | EP | claimed |
| WO-2006055690-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MICROVENTION, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20060105014-A1 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2006-05-18 | — | — | US | claimed |
| US-20060063914-A1 | specifically conjugating polyethylene glycol to targeted sites of the synthetic peptides; pegylation; synthetic peptides having selectively protected amines of untargeted sites | PEGSPHERE CO., LTD. (KR) | 2006-03-23 | — | — | US | claimed |
| EP-1585758-A1 | PEPTIDES HAVING PROTECTED AMINES OF UNTARGETED SITES, METHODS FOR PRODUCTION THEREOF AND OF SPECIFICALLY CONJUGATED PEG PEPTIDES USING THE SAME | PEGSPHERE Co., Ltd. (KR) | 2005-10-19 | — | — | EP | claimed |
| EP-1578450-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | Access Pharmaceuticals Australia Pty Ltd (AU) | 2005-09-28 | — | — | EP | claimed |
| WO-2004065412-A1 | PEPTIDES HAVING PROTECTED AMINES OF UNTARGETED SITES, METHODS FOR PRODUCTION THEREOF AND OF SPECIFICALLY CONJUGATED PEG PEPTIDES USING THE SAME | PEGSPHERE CO., LTD. (KR) | 2004-08-05 | — | — | WO | claimed |
| WO-2004045647-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2004-06-03 | — | — | WO | claimed |
| CN-118043084-A | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2024-05-14 | — | — | CN | disclosed |
| CN-118043068-A | RNA vaccine | 阿克丘勒斯治疗公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024094027-A1 | BLOCKING SEQUENCE, KIT THEREOF, AND METHOD FOR USING SAME | 深圳鸿生生物科技有限公司 | 2024-05-10 | — | — | WO | disclosed |
| EP-0067029-B1 | OXYGEN CARRIER | AJINOMOTO CO., INC. (JP) | 1986-04-30 | — | — | EP | disclosed |
| US-4412989-A | POLYOXYALKYLENE GLYCOL COUPLED TO A HEMOGLOBIN OR HEMOGLOBIN DERIVATIVE | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-11-01 | — | — | US | disclosed |
| EP-0067029-A2 | Oxygen carrier | AJINOMOTO CO., INC. (JP) | 1982-12-15 | — | — | EP | disclosed |